|
|
|
|
||
4th BioCentury China healthcare conferenceCAN CHINA TRANSITION FROM ME TOO TO ME FIRST? While many of China's first wave of biotech startups focused on "me too" or "me better" products, a next generation of companies is shifting towards global innovation. How long will it take for China to build a critical mass of first-in-class startups? What are some key factors for success? Meng JIANG, Managing Director, C-Bridge Capital Partners (Session Co-Chair & Moderator) Jimmy Wei, Ph.D., Managing Partner, I-Bridge Capital (Session Co-Chair & Moderator) Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund John Oyler, Chairman, Founder & CEO, BeiGene Ltd. Lei XIAO, Ph.D., Chairman & CSO, Innovative Cellular Therapeutics Co. Ltd. Ting XU, Ph.D., Chairman & CEO, Alphamab Co. Ltd. Jingwu ZANG, M.D., Ph.D., Founder & CEO, I-Mab Biopharma This presentation took place on 11/15. I'd imagine Bin Li was stumping for BIOC... Check out the conference website - everyone who is anyone in Chinese pharma tech was in attendance... https://www.biocentury.com/conferences/china-healthcare-summit-2017/speakers |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
807 | Re: 4th BioCentury China healthcare conference | Aces_up_222 | 0 | 11/17/2017 4:13:33 PM |